By: Mitch Gabanic On December 10th, the United States Patent and Trademark Office (USPTO) released its plan to modernize the…
Intellectual Property firm Meunier Carlin & Curfman LLC (“MCC”) earned several recognitions in the latest U.S. News – Best Lawyers…
By: Shirlene Jackson-Beckford PhD The USPTO has announced an increase to its official fees which will come into effect on…
Increased patent fees apply on January 16, 2018.
Heat-reflective materials in sportswear was contested in a design and utility patent case.
The U.S. became a member of the Geneva Act of the Hague Agreement in May 2015. U.S. applicants can now take advantage of a centralized procedure for global examination of design applications.
The USPTO recently released its 2014 Interim Guidance on Patent Subject Matter Eligibility.
Meunier Carlin & Curfman client Oncolytics Biotech Inc. of Calgary, Alberta, Canada, the assignee of US Patent No. 7,803,385 directed to a modified reovirus for the treatment of cancer, finally received a Certificate of Correction from the US Patent and Trademark Office (USPTO) showing 122 days of patent term adjustment, a patent term adjustment originally and repeatedly denied by the USPTO.
Chris Curfman discusses key provisions of the America Invents Act, recently signed into law.
The decision was handed down by the Supreme Court after a long wait on June 28, 2010. The Court upheld the Federal Circuit’s ruling that the claims at issue were not patentable subject matter. For proponents of reduced patent coverage for business method claims it was a Pyrrhic victory.